MiniMed Group, Inc.(MMED)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,930 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MMED Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for MiniMed Group, Inc. (MMED), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MMED at 44.2/100 on a 32-signal composite quality model, placing it at rank #1,930 of 2,962 stocks — the bottom half of the AI-ranked universe. MMED scores in the top quartile across revenue growth (92.1). Areas of concern include profitability (30.0) and free cash flow (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MiniMed Group, Inc. reports quarterly revenue of $843.0M, net income of $0.00, an operating margin of 0.6%. Top institutional holders of MMED by reported 13-F value include MASSACHUSETTS FINANCIAL SERVICES, MILLENNIUM MANAGEMENT, CITADEL ADVISORS, based on the most recent SEC filings. MMED trades on the Nasdaq exchange and files with the SEC under CIK 2062583. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MMED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MiniMed Group, Inc. directly from SEC EDGAR. MiniMed Group, Inc.'s 13F Pro composite quality score has ranged between 42 and 44 since 2026, currently 44.2 — a stable long-term trajectory across 13 quarterly and live scoring snapshots.
Revenue
Q2 2026
$843.0M
Net Income
Q2 2026
$0.00
Free Cash Flow
Q2 2026
$-90.0M
Operating Margin
Q2 2026
0.6%
ROIC
Q2 2026
0.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+14.3% YoYNet Income
-56.3% YoYOperating Income
-30.1% YoYEPS (Diluted)
-54.8% YoYTotal Assets
+10.2% YoYOp. Cash Flow
-240.7% YoYFree Cash Flow
-692.5% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue | $3.10B +14.3% | $2.71B +10.0% | $2.47B | — |
| Net Income | $-333.0M -56.3% | $-213.0M -90.2% | $-112.0M | — |
| Operating Income | $-190.0M -30.1% | $-146.0M -111.6% | $-69.0M | — |
| EPS (Diluted) | $-1.30 -54.8% | $-0.84 -90.9% | $-0.44 | — |
| Total Assets | $4.63B +10.2% | $4.20B | — | — |
| Operating Cash Flow | $-197.0M -240.7% | $140.0M +241.5% | $41.0M | — |
| Free Cash Flow | $-420.0M -692.5% | $-53.0M +50.5% | $-107.0M | — |
Get alerted when MMED's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MiniMed Group, Inc. including:
Top Institutional Holders of MMED
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$124.6M8,334,738 shMILLENNIUM MANAGEMENT LLC
$45.8M3,060,615 shCITADEL ADVISORS LLC
$42.8M2,865,703 shLongaeva Partners L.P.
$42.1M2,812,970 shSessa Capital IM, L.P.
$29.9M2,000,000 shBlackRock, Inc.
$29.8M1,996,489 shNORGES BANK
$29.3M1,961,002 shRock Springs Capital Management LP
$22.7M1,520,000 shExodusPoint Capital Management, LP
$21.5M1,437,067 shFMR LLC
$16.2M1,080,689 sh
| Fund | Value | Shares |
|---|---|---|
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $124.6M | 8,334,738 |
| MILLENNIUM MANAGEMENT LLC | $45.8M | 3,060,615 |
| CITADEL ADVISORS LLC | $42.8M | 2,865,703 |
| Longaeva Partners L.P. | $42.1M | 2,812,970 |
| Sessa Capital IM, L.P. | $29.9M | 2,000,000 |
| BlackRock, Inc. | $29.8M | 1,996,489 |
| NORGES BANK | $29.3M | 1,961,002 |
| Rock Springs Capital Management LP | $22.7M | 1,520,000 |
| ExodusPoint Capital Management, LP | $21.5M | 1,437,067 |
| FMR LLC | $16.2M | 1,080,689 |
Companies Similar to MMED
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
TELEFLEX INC
SHOULDER INNOVATIONS, INC.
CARLSMED, INC.
Alphatec Holdings, Inc.
PTC THERAPEUTICS, INC.
Tarsus Pharmaceuticals, Inc.
ARDELYX, INC.
TANDEM DIABETES CARE INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MMED on your watchlist
Track score changes the day MiniMed Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MMED a good stock to buy?
13F Pro's AI-powered analysis of MiniMed Group, Inc. (MMED) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MMED are available on the MMED stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MMED is classified as a mid company.
Which hedge funds own MMED?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MMED. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MiniMed Group, Inc.'s investment landscape.